

Haematologica  
HAEMATOL/2019/242453  
Version 4

Bi 38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicities for the treatment of multiple myeloma.

Maxime Fayon, Carolina Martinez-Cingolani, Audrey Abecassis, Nathalie Roders, Elisabeth Nelson, Caroline Choisy, Alexis Talbot, Armand Bensussan, Jean-Paul Fermand, Bertrand Arnulf, and Jean-Christophe Bories

Disclosures: 1. This work was supported by grant from the “Cancéropole Ile de France” and from the “Fondation Française pour la Recherche contre le Myélome et les Gammopathies monoclonales”. M. Fayon and C. Martinez-Cingolani were supported by fellowships from the French “Agence National pour la Recherche”, programme d’Investissements d’avenir (ANR-10-IDEX-03-02). M. Fayon was also supported by a fellowship from the “Société Française d’Hématologie”. A. Abecassis was supported by a fellowship from the “Agence Nationale pour la Recherche Scientifique, CIFRE” in partnership with Servier. 2. A. Abecassis is funded by Servier. 3. Patent N°: EP19186591

Contributions: M. Fayon, C. Martinez-Cingolani and J.C. Bories designed the study. M. Fayon and C. Martinez-Cingolani performed all the experiments. A. Bensussan provided the anti-CD38 hybridoma. A. Abecassis and N. Roders contributed to the functional assay. Elisabeth Nelson and Caroline Choisy performed mouse works. A. Talbot, JP. Fermand and Bertrand Arnulf provided samples from MM patients. M. Fayon, C. Martinez-Cingolani and J.C. Bories interpreted the data, designed the figures, and drafted the manuscript.